)
)
Thor Medical Investor Relations Material
Latest events
Q2 2024
Thor Medical
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Thor Medical
Access all reports
Segment Data
Access more data
Non-current assets by
Geography
Norway
Expenses by
Financials
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutic products for hematological cancers in Norway. The company is developing Betalutin, an antibody radionuclide conjugate, which is in Phase III clinical trial for a range of non-Hodgkin lymphoma indications. It is also developing 177Lu-lilotomab satetraxetan (HH1), a targeted alpha immunotherapy for non-Hodgkin lymphomas. The company has strategic collaboration with NRCF to develop treatment regimens for hematological cancers and other indications using Lutathera or Betalutin; and with Servier S.A.S., as well as Cytodyn Inc.
Key slides for Thor Medical
Q4 2023
Thor Medical
Q2 2024
Thor Medical
Latest articles
)
House of Warhammer: The Inner Workings of Games Workshop
A look under the hood of Games Workshop, a high-margin business in an incredibly niche market, with sky-high stock returns.
15 Nov 2024
)
Crafting a Solid Equity Story: A Strategic Guide for Investor Relations Professionals
Craft a compelling equity story: Align narratives with data to attract ideal investors and build trust with Quartr Pro's powerful IR tools.
13 Nov 2024
)
Our List of 100 Eminent Serial Acquirers
Serial acquirers have deep experience in mastering value creation through reallocating resources across their portfolio of acquired companies.
12 Nov 2024
Ticker symbol
TRMED
Country
🇳🇴 Norway